Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source



Status:Recruiting
Conditions:Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/17/2019
Start Date:September 6, 2017
End Date:December 31, 2020
Contact:Carra Castagnero
Email:ccastagnero@tabclinical.com
Phone:9193145515

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Initial Feasibility Study to Treat Resectable Pancreatic Cancer With the Permanently Implantable LDR CivaSheet®

This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that
utilizes active components (Palladium-103) of standard devices in a novel configuration. This
study may benefit resectable pancreatic cancer patients by reducing the radiation dose to
adjacent critical structures, while giving a therapeutic dose to diseased tissue, such as at
a surgical margin.


Inclusion Criteria:

- Subject signed informed consent

- Age >/= 18 years

- Biopsy confirmed adenocarcinoma pancreatic cancer

- Patient capable of undergoing anesthesia

- Patient is a surgical candidate

- Patient selected to undergo pancreatic cancer resection

- Patient will have known or suspected close/positive surgical margin

- Confirmed diagnosis of resectable pancreatic adenocarcinoma

- Will be prescribed standard Gemcitabine 1000 mg/m2 chemotherapy cycle

Exclusion Criteria:

- Pregnant or breast feeding

- Patient has metastatic disease

- Patient has had prior radiation therapy to the region for separate cancer

- Patient has had prior chemotherapy

- Any other invasive cancer in the past 5 years, except basal cell skin

- Recurrent or previously resected tumors

- Alcoholism/Drug abuse
We found this trial at
1
site
East Carolina University Brody School of Medicine
Greenville, North Carolina
Principal Investigator: Emmanuel Zervos
Phone: 252-744-5723
?
mi
from
Greenville, NC
Click here to add this to my saved trials